

Comment

To sanco-pharmaceuticals-d5@ec.europa.eu
sanco-pharmaceuticals-d6@ec.europa.eu
Fabio Datri
Stefan Führung

From Thomas Brückner

CC Dr. Norbert Gerbsch, BPI.
Dr. Rainer Oschmann, Wilm. Schwabe GmbH & Co. KG.

Subject Comments on the Delegated act on the detailed rules for
a unique identifier for medicinal products for human use,
and its verification/ concept paper submitted for public
consultation (Sanco.ddg1.d.3(2011)1342823)

Date 27.04.2012

Friedrichstraße 148
10117 Berlin
www.bpi.de

Medizin und Pharmazie

Telefon: (0 30) 2 79 09-1 13

Telefax: (0 30) 2 79 09-3 13

E-Mail: tbrueckner@bpi.de

Dear Sirs,

To whom it may concern

The German Pharmaceutical Industry Association (BPI) is a both nationally and internationally acting industry association representing the interests of 280 pharmaceutical companies.

BPI is grateful for the opportunity to comment on the EU Concept Paper on the Delegated act on the detailed rules for a unique identifier for medicinal products for human use, and its verification (Sanco.ddg1.d.3(2011)1342823).

Please find our comments in the attached table.

Kind regards



Thomas Brückner
Head of Pharmaceutical Affairs/
Medical Devices/ CAM